Thus, it is intriguing to propose that CFTR therapeutics could represent a safe means of improving neurological symptoms, reducing the incidence and severity of strokes, and minimizing long-term cognitive impact in COVID-19 patients. The gene discussed is CFTR; the disease is COVID-19.